Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
50g |
|
||
Other Sizes |
|
Purity: ≥98%
Phenylephrine HCl (Metaoxedrine chloride; NCIc-55641; NCI c55641; Neosympatol; Oftalfrine; Mezaton; Neo Synephrine; Neo-Synephrine), the hydrochloride salt of Phenylephrine, is a potent and selective α1-adrenergic receptor agonist that is primarily used as a decongestant. It is a nasal decongestant, mydriatic, and cardiotonic agent.
Targets |
α adrenergic receptor
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References | |||
Additional Infomation |
Phenylephrine hydrochloride is an odorless white microcrystalline powder. Bitter taste. pH (1% aqueous solution) about 5. (NTP, 1992)
Phenylephrine Hydrochloride is the hydrochloride salt form of phenylephrine, a direct-acting sympathomimetic amine chemically related to adrenaline and ephedrine with potent vasoconstrictor property. Phenylephrine is a post-synaptic alpha-adrenergic receptor agonist that causes vasoconstriction, increases systolic/diastolic pressures, reflex bradycardia, and stroke output. An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. See also: Phenylephrine (has active moiety); Ibuprofen; PHENYLEPHRINE HYDROCHLORIDE (component of); Phenylephrine Hydrochloride; Tropicamide (component of) ... View More ... |
Molecular Formula |
C9H14CLNO2
|
|
---|---|---|
Molecular Weight |
203.67
|
|
Exact Mass |
203.071
|
|
Elemental Analysis |
C, 53.08; H, 6.93; Cl, 17.41; N, 6.88; O, 15.71
|
|
CAS # |
61-76-7
|
|
Related CAS # |
Phenylephrine-2,4,6-d3 hydrochloride; 1276197-50-2; Phenylephrine; 59-42-7; Phenylephrine-d3 hydrochloride; 1217858-50-8; (S)-Phenylephrine-d6 hydrochloride; Phenylephrine-d6 hydrochloride; 1089675-56-8
|
|
PubChem CID |
5284443
|
|
Appearance |
White to off-white solid powder
|
|
Boiling Point |
341.1ºC at 760 mmHg
|
|
Melting Point |
143-145 °C(lit.)
|
|
Flash Point |
163.4ºC
|
|
Index of Refraction |
-45.5 ° (C=1, H2O)
|
|
LogP |
1.837
|
|
Hydrogen Bond Donor Count |
4
|
|
Hydrogen Bond Acceptor Count |
3
|
|
Rotatable Bond Count |
3
|
|
Heavy Atom Count |
13
|
|
Complexity |
130
|
|
Defined Atom Stereocenter Count |
1
|
|
SMILES |
Cl[H].O([H])[C@]([H])(C1C([H])=C([H])C([H])=C(C=1[H])O[H])C([H])([H])N([H])C([H])([H])[H]
|
|
InChi Key |
OCYSGIYOVXAGKQ-FVGYRXGTSA-N
|
|
InChi Code |
InChI=1S/C9H13NO2.ClH/c1-10-6-9(12)7-3-2-4-8(11)5-7;/h2-5,9-12H,6H2,1H3;1H/t9-;/m0./s1
|
|
Chemical Name |
3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.9099 mL | 24.5495 mL | 49.0990 mL | |
5 mM | 0.9820 mL | 4.9099 mL | 9.8198 mL | |
10 mM | 0.4910 mL | 2.4550 mL | 4.9099 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01791816 | Active Recruiting |
Drug: Phenylephrine Drug: L-Ng-monomethyl Arginine (L-NMMA) |
Vasovagal Syncope Postural Tachycardia Syndrome |
New York Medical College | February 2013 | Early Phase 1 |
NCT03620942 | Active Recruiting |
Drug: Phenylephrine Drug: Ephedrine |
Hypotension Anesthesia |
KK Women's and Children's Hospital |
November 7, 2018 | Not Applicable |
NCT05011357 | Recruiting | Drug: Phenylephrine Drug: Saline Control |
Intraoperative Hypotension | University of Texas Southwestern Medical Center |
September 10, 2021 | Early Phase 1 |
NCT02630121 | Recruiting | Drug: Oxymetazoline Hydrochloride Drug: Placebo |
Sleep Apnea Chronic Nasal Congestion |
University of South Florida | April 2023 | Phase 4 |
NCT04602767 | Recruiting | Drug: Vasopressin Drug: Phenylephrine |
Acute Kidney Injury | Thomas Jefferson University | October 15, 2020 | Phase 4 |